AITX's RAD Dominates ISC West with Major Awards and Surge in Enterprise Leads
RAD Secures Over 300 Qualified Leads at ISC West 2025
Detroit, Michigan--(Newsfile Corp. - April 7, 2025) - Robotic Assistance Devices, Inc. (RAD), a subsidiary of Artificial Intelligence Technology Solutions, Inc. (OTC Pink: AITX) (the "Company"), achieved a major milestone at ISC West 2025, the premier event for security professionals. RAD earned both the Best in Threat Detection and Response Solutions award and the prestigious Judges' Choice Award at the SIA New Product Showcase, with its SARA™ (Speaking Autonomous Responsive Agent) recognized as the standout innovation of the entire show.
Steve Reinharz, CEO/CTO of AITX and RAD, holds the SIA Judges' Choice Award earned by SARA, the AI Security Agent, during ISC West 2025, presented in the SARA Experience Zone at the RAD booth.
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/5243/247532_c97eb4e1b4ee683a_001full.jpg
These accolades reflect RAD's continued leadership in redefining physical security through artificial intelligence, robotics, and automation.
Beyond the awards, RAD connected with over 300 new prospects at the event, each verified and requesting follow-up. Nearly 50 of these prospects represent Fortune 1000 organizations, including six Fortune 50 companies not currently doing business with RAD. The volume and caliber of interest signal a rapid expansion of RAD's visibility and appeal across enterprise and institutional markets.
Widespread Industry Engagement
RAD's powerful lineup of solutions, including ROAMEO™, RIO™, AVA™, SARA, ROSA™, and its Firearm Detection analytic, sparked compelling conversations across numerous sectors:
Enterprise & Corporate Facilities: Multiple global organizations expressed strong interest in RAD's ability to automate perimeter patrols, improve visitor access control, and streamline monitoring operations through AI-driven systems.
Government & Scientific Institutions: Organizations overseeing critical infrastructure and space operations identified RAD's autonomous units as effective tools for safeguarding high-value assets and enhancing situational awareness.
Healthcare Networks: Several leading healthcare systems prioritized RAD's solutions for securing hospital exteriors and parking areas, with urgent deployment requests for ROAMEO, RIO and RAD Light My Way™.
Logistics & Transportation: Major providers initiated RFP discussions focused on modernizing entry and exit operations, aiming to reduce reliance on manned guard stations by deploying RAD's integrated platforms.
Retail & Commercial Properties: Large retail chains outlined plans to replace parking lot guards with autonomous patrol units, citing RAD's effectiveness in enhancing deterrence and improving overall safety.
Aerospace & Defense: Operators of secure facilities and industrial campuses evaluated ROAMEO and RIO for deployment in perimeter and parking zone protection, recognizing the value of autonomous coverage in high-security environments.
Entertainment & Venues: Event venues and stadiums prioritized rapid integration of RAD solutions, including Security Operations Center (SOC) enhancements with SARA and active on-site deterrence using RIO and ROAMEO.
Market Trends Confirm RAD's Direction
Conversations throughout the event reinforced RAD's position at the forefront of security innovation, with recurring themes including:
Guard Force Reduction: Organizations are actively shifting toward automation to reduce dependency on traditional guard services and improve operational efficiency.
Parking & Perimeter Safety: Interest in ROAMEO and RIO continues to grow as organizations look to secure expansive, high-risk areas with solutions that offer consistent coverage and active deterrence.
AI-Driven Security Monitoring: Organizations are increasingly prioritizing real-time analytics and proactive, intelligent alerting as essential components of modern security strategies.
"Winning both our category and the overall Judges' Choice Award at ISC West is an extraordinary honor," said Steve Reinharz, CEO/CTO of AITX and RAD. "But what excites us even more is the overwhelming response from top-tier companies and institutions that see RAD as the future of security and automation."
AITX, through its subsidiary, Robotic Assistance Devices, Inc. (RAD), is redefining the nearly $50 billion (US) security and guarding services industryi through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide cost savings to businesses of between 35%-80% when compared to the industry's existing and costly manned security guarding and monitoring model. RAD delivers these tremendous cost savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house.
RAD has a prospective sales pipeline of over 35 Fortune 500 companies and numerous other client opportunities. RAD expects to continue to attract new business as it converts its existing sales opportunities into deployed clients generating a recurring revenue stream. Each Fortune 500 client has the potential of making numerous reorders over time.
About Artificial Intelligence Technology Solutions (AITX)
AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX's RAD, RAD-R, RAD-M and RAD-G companies help organizations streamline operations, increase ROI, and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staff and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education, and healthcare. To learn more, visit www.aitx.ai, www.radsecurity.com, www.stevereinharz.com, www.radgroup.ai, www.raddog.ai, and www.radlightmyway.com, or follow Steve Reinharz on Twitter @SteveReinharz.
CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS
The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Artificial Intelligence Technology Solutions, Inc. (the "Company"). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.
###
Steve Reinharz949-636-7060@SteveReinharz
________________________i https://www.ibisworld.com/united-states/market-research-reports/security-services-industry/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247532
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
China auto stocks rise as they pledge faster supplier payments
-- China auto stocks rose Wednesday after major car companies committed to shortening payment terms for suppliers amid an intensifying price war in China's auto market. Guangzhou Automobile Group Co Ltd (HK:2238) announced late Tuesday that it would pay suppliers within 60 days, a measure designed to ensure efficient capital flow across auto industry supply chains. Government-owned companies Dongfeng Motor Group Co (OTC:DNFGF) Ltd (OTC:DNFGY) and China FAW Group made similar commitments. The initiative gained momentum Wednesday when electric vehicle manufacturer BYD Co (SZ:002594) Ltd-H (HK:1211), along with Li Auto Inc (NASDAQ:LI) and Xiaomi (OTC:XIACF) Corp (HK:1810), also pledged to follow the 60-day payment schedule. More than 10 Chinese auto companies have now agreed to this payment term. The stock market responded positively to these announcements. BYD shares rose 4.6% in Hong Kong trading, while Guangzhou Automobile Group climbed 1.8% and Dongfeng Motor gained 1.7%. These payment commitments came shortly after the China Iron and Steel Association raised concerns about how the latest round of price cuts by Chinese EV makers was affecting supply chain operations. In a WeChat statement Tuesday, the association warned that the ongoing EV price war would force iron and steel companies to reduce their prices, putting additional pressure on profit margins. The statement also pointed out that Chinese EV manufacturers have been delaying payments, creating financial strain for upstream suppliers. Related articles China auto stocks rise as they pledge faster supplier payments Musk apology to Trump could reopen path for renewed alliance says Dan Ives Ouster shares surge on Pentagon approval for lidar sensor Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Lifordi Immunotherapeutics Presents Preclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 to Treat Autoimmune and Inflammatory Diseases at EULAR 2025
Burlington, Massachusetts--(Newsfile Corp. - June 11, 2025) - Lifordi Immunotherapeutics, Inc., a biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, presented preclinical data on its lead program for LFD-200, an ADC delivering a potent glucocorticoid (GC) directly to immune cells. Results of multiple in vitro and in vivo studies in mice and in non-human primates (NHPs) demonstrated that LFD-200 achieves targeted and sustained delivery of its GC payload to immune cells, resulting in efficacy without systemic toxicity. These data were presented at the European Alliance of Associations for Rheumatology (EULAR) meeting in Barcelona. To view the full announcement, including downloadable images, bios, and more, click here. Click image above to view full announcement. About Lifordi Lifordi Immunotherapeutics, Inc. is leading the way in leveraging the success of antibody-drug conjugates (ADCs) to develop treatments for autoimmune and inflammatory disorders. The Company's lead ADC, LFD-200, has demonstrated efficacy in multiple preclinical disease models by targeting myeloid and lymphoid cells using a highly internalized cell surface membrane protein (VISTA). Lifordi has also applied its novel drug delivery platform to other diverse payloads, such as small molecules, antisense oligonucleotides (ASOs) and siRNA. As experienced drug developers in immunology and inflammatory diseases, together with expert clinical advisors, a strong partnering track record, and funding from ARCH Venture Partners, 5AM Ventures, and Atlas Venture to support initial clinical data, Lifordi is committed to changing how immune and inflammatory diseases are treated. For more information, please visit Contacts: Theresa McNeely tmcneely@ Source: Lifordi To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
an hour ago
- Hamilton Spectator
Repeat: Treatment.com AI Announces New Medical Education Suite to Enhance Clinical Skills Training Through AI-Simulated Patients
VANCOUVER, BC, June 11, 2025 (GLOBE NEWSWIRE) — AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) ('Treatment') is pleased to announce that it has released its latest version of the Medical Education Suite (MES). The University of Minnesota Medical School has successfully completed a live deployment of AI's new Medical Education Suite (MES), an AI-powered clinical skills assessment platform designed to support medical schools in delivering scalable, rigorous, and cost-effective Objective Structured Clinical Examinations (OSCEs). The deployment, conducted with over 240 third-year medical students, marked the first large-scale implementation of computer-simulated patient cases developed through the Global Library of Medicine (GLM), a clinician-built medical knowledge engine. The exams ran with complete technical reliability during deployment, as well as integrating seamlessly into the school's existing OSCE workflow. 'Our goal is to support medical schools by applying our clinical experience and AI expertise to real educational challenges.' stated Dr. Kevin Peterson, Founder and Chief Medical Officer of AI. 'The Medical Education Suite reflects years of development in diagnostic reasoning and knowledge engineering. By introducing structured, AI-simulated patients alongside live simulated patients, and offering objective real-time scoring, we're helping students build stronger clinical skills in the classroom and giving educators the trusted healthcare education software needed to teach and assess clinical content and behavioral approaches to complex clinical problems with confidence.' The MES is a scalable platform designed to reduce administrative and faculty time, improve objectivity, increase evaluation consistency, and provide a robust digital infrastructure to support both live and AI-simulated formats. The focus of the platform is to help enhance the clinical skills of our next generation of healthcare professionals. By incorporating curated AI-generated cases and the supportive services provided by Treatment, the system enables: 'Partnering with AI gave us the opportunity to explore how clinically governed AI can strengthen the way we assess and support student learning. The MES allowed us to deliver a high-stakes OSCE at scale, while ensuring consistent, objective evaluation aligned with our academic standards. The MES represents a meaningful step forward in the evolution of medical education.' said Professor Claudio Violato, Assistant Dean, University of Minnesota Medical School. 'We look forward to sharing our findings.' The MES combines AI-simulated patients with automated feedback, helping faculty assess diagnostic and management reasoning, clinical prioritization, and documentation quality, all mapped to learning objectives. Early feedback suggests that the platform enhances the student learning experience and strengthens the reliability of OSCE results. Preliminary results of the accuracy and precision of the GLM as applied in the MES platform were presented at the AAMC's 2025 Group on Information Resources meeting. Prof. Violato, Dr. Peterson, and their respective teams are preparing further scientific publications detailing the methodology, deployment, and outcomes of the UMN program. AI is engaging with a wide variety of other schools, with the goal to extend the MES offering across North America, the UK, and to other international OSCE markets. About AI Inc. AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. AI's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. Learn more at: or contact . About University of Minnesota Medical School Founded in 1888, the University of Minnesota Medical School is one of the nation's largest, with three campuses in Minneapolis, Duluth, and St. Cloud. It enrolls first- and second-year students at Duluth and St. Cloud, and carries clinical training at the Twin Cities campus and affiliated hospitals. The school educates future physicians through MD, graduate, undergraduate, and continuing professional development programs, supported by over 3,000 faculty members and 20+ research centers and institutes. Its core mission is to improve health through exceptional education, compassionate patient care, and leading-edge biomedical research, particularly focusing on primary care, specialty medicine, rural communities, and American Indian/Alaska Native populations. The school is nationally recognized for its NIH-funded research (ranked #21 overall, #2 among public medical schools) and emphasizes interprofessional, community-based training while promoting equity and access across diverse populations. Learn more at: FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO – AI Inc. Email: Media inquiries: Sales: Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statement This news release contains forward-looking statements that are based on AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although AI believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
